Intuitive Surgical (ISRG) to Release Earnings on Thursday

Intuitive Surgical (NASDAQ:ISRG) is scheduled to be releasing its earnings data after the market closes on Thursday, October 17th. Analysts expect Intuitive Surgical to post earnings of $1.65 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the company posted $1.18 EPS. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, analysts expect Intuitive Surgical to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Intuitive Surgical Stock Up 0.6 %

ISRG opened at $487.61 on Tuesday. The business has a fifty day moving average of $481.33 and a 200 day moving average of $435.81. Intuitive Surgical has a 52-week low of $254.85 and a 52-week high of $496.48. The stock has a market cap of $172.96 billion, a P/E ratio of 88.02, a PEG ratio of 5.40 and a beta of 1.39.

Insiders Place Their Bets

In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 in the last ninety days. Insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Citigroup upped their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Evercore ISI upped their target price on Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. BTIG Research upped their target price on Intuitive Surgical from $494.00 to $518.00 and gave the company a “buy” rating in a research report on Monday. Raymond James increased their price target on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Morgan Stanley raised their target price on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $467.55.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.